NC9 treatment produces a marked reduction in tumor formation (Figure 5G, 5H) and this is associated with a parallel reduction in stem cell (Sox-2, Oct-4) and EMT (fibronectin, N-cadherin, Slug and Twist) marker levels (Figure 5I). The gene discussed is SOX2; the disease is neoplasm.